

## Q4 and Full-Year 2024 Earnings

### Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

#### 2024 ACTUAL RESULTS

CVS Health Corporation (the “Company”) uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance. These non-GAAP financial measures are provided as supplemental information to the financial measures the Company discloses that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measurements reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (“EPS”) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.

#### LEVERAGE RATIO CALCULATION

The Company defines Leverage Ratio as Adjusted Net Debt divided by adjusted earnings before interest, tax, depreciation and amortization (Adjusted EBITDA). Adjusted Net Debt is defined as short-term debt and total long-term debt, including the current portion of long-term debt (GAAP measure), less a fifty percent equity credit for junior subordinated notes outstanding, plus the current and long-term portion of operating lease liabilities (GAAP measure) reported on the Company’s consolidated balance sheets, plus the present value of payments related to agreements to resolve substantially all opioid claims against the Company (the “opioid litigation liabilities”), less cash and cash equivalents held by the parent company or nonrestricted subsidiaries. Adjusted EBITDA is defined as (i) net income (GAAP measure) plus income taxes, interest, depreciation and amortization plus (ii) operating lease costs, and (iii) other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges, losses on assets held for sale, gains on early extinguishment of debt and any other items specifically identified herein. The following are reconciliations of total debt to Adjusted Net Debt and net income to Adjusted EBITDA as well as a calculation of Adjusted Net Debt to Adjusted EBITDA as of December 31, 2024 and 2023:

#### Adjusted Net Debt-to-EBITDA

##### Adjusted Net Debt

<i>In millions</i>	As of December 31,	
	2024	2023
Total debt (GAAP Measure) <sup>(1)</sup>	\$ 66,270	\$ 61,610
Equity credit for junior subordinated notes <sup>(2)</sup>	(1,500)	—
Operating lease liabilities (GAAP Measure) <sup>(3)</sup>	16,650	17,775
Opioid litigation liabilities <sup>(4)</sup>	3,103	3,198
Less: Cash & cash equivalents held by the parent Company or nonrestricted subsidiaries	(3,750)	(735)
<b>Adjusted Net Debt</b>	<b>\$ 80,773</b>	<b>\$ 81,848</b>

## Q4 and Full-Year 2024 Earnings

### Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

#### Adjusted EBITDA

<i>In millions</i>	Years Ended December 31,	
	2024	2023
Net income (GAAP Measure)	\$ 4,586	\$ 8,368
Income tax provision	1,562	2,805
Interest expense	2,958	2,658
Depreciation and amortization	4,597	4,366
<b>EBITDA</b>	<b>13,703</b>	<b>18,197</b>
Operating lease cost <sup>(6)</sup>	2,423	2,532
Acquisition-related transaction and integration costs <sup>(7)</sup>	243	487
Restructuring charges <sup>(8)</sup>	1,179	507
Office real estate optimization charges <sup>(9)</sup>	30	46
Opioid litigation charges <sup>(10)</sup>	100	—
Gain on early extinguishment of debt <sup>(5)</sup>	(491)	—
Loss on assets held for sale <sup>(11)</sup>	—	349
<b>Adjusted EBITDA</b>	<b>\$ 17,187</b>	<b>\$ 22,118</b>

#### Adjusted Net Debt-to-EBITDA

<i>In millions (except leverage ratio)</i>	As of December 31,	
	2024	2023
Adjusted Net Debt	\$ 80,773	\$ 81,848
Adjusted EBITDA	\$ 17,187	\$ 22,118
<b>Adjusted Net Debt-to-EBITDA</b>	<b>~4.70x</b>	<b>~3.70x</b>

## Q4 and Full-Year 2024 Earnings Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

---

### CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. The information on pages 4 to 6 of this document is forward-looking. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in the Company’s most recently filed Annual Report on Form 10-K and its other filings with the SEC.

You are cautioned not to place undue reliance on the Company’s forward-looking statements. The Company’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

## Q4 and Full-Year 2024 Earnings

### Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

#### FULL-YEAR 2025

#### ADJUSTED EARNINGS PER SHARE

GAAP diluted EPS and Adjusted EPS, respectively, are calculated by dividing net income attributable to CVS Health and adjusted income attributable to CVS Health by the Company's weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges, gains on early extinguishment of debt and the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health, as well as any other items specifically identified herein.

The following are reconciliations of projected GAAP diluted EPS to projected Adjusted EPS:

	2025E		2024
	Low	High	Actual
	Per Common Share		
<i>In millions, except per share amounts</i>			
Net income attributable to CVS Health (GAAP measure)	\$ 4.58	\$ 4.83	\$ 3.66
<i>Non-GAAP adjustments:</i>			
Amortization of intangible assets	1.59	1.59	1.61
Net realized capital gains	—	—	(0.09)
Acquisition-related integration costs <sup>(7)</sup>	0.11	0.11	0.19
Restructuring charges <sup>(8)</sup>	—	—	0.93
Office real estate optimization charges <sup>(9)</sup>	0.01	0.01	0.02
Opioid litigation charges <sup>(10)</sup>	—	—	0.08
Gain on early extinguishment of debt <sup>(5)</sup>	—	—	(0.39)
Tax impact of non-GAAP adjustments <sup>(12)</sup>	(0.54)	(0.54)	(0.59)
Adjusted income attributable to CVS Health	<u>\$ 5.75</u>	<u>\$ 6.00</u>	<u>\$ 5.42</u>
Weighted average diluted shares outstanding	1,271	1,271	1,262

## Q4 and Full-Year 2024 Earnings

### Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

#### ADJUSTED OPERATING INCOME

The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related integration costs, restructuring charges, office real estate optimization charges and opioid litigation charges. The Company's chief operating decision maker ("CODM") uses adjusted operating income as its principal measure of segment performance as it enhances the CODM's ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. The following are reconciliations of projected operating income to projected adjusted operating income:

#### FULL-YEAR 2025

#### CONSOLIDATED

<i>In millions</i>	Year Ending December 31,		
	2025E		2024
	Low	High	Actual
Operating income (GAAP measure)	\$ 10,775	\$ 11,225	\$ 8,516
Amortization of intangible assets	2,025	2,025	2,025
Net realized capital gains	—	—	(117)
Acquisition-related integration costs <sup>(7)</sup>	135	135	243
Restructuring charges <sup>(8)</sup>	—	—	1,179
Office real estate optimization charges <sup>(9)</sup>	15	15	30
Opioid litigation charges <sup>(10)</sup>	—	—	100
<b>Adjusted operating income</b>	<b>\$ 12,950</b>	<b>\$ 13,400</b>	<b>\$ 11,976</b>

#### HEALTH CARE BENEFITS SEGMENT

<i>In millions</i>	Year Ending December 31,		
	2025E		2024
	Low	High	Actual
Operating income (GAAP measure)	\$ 309	\$ 759	\$ (984)
Amortization of intangible assets	1,178	1,178	1,175
Net realized capital losses	—	—	97
Office real estate optimization charges <sup>(9)</sup>	13	13	19
<b>Adjusted operating income</b>	<b>\$ 1,500</b>	<b>\$ 1,950</b>	<b>\$ 307</b>

## Q4 and Full-Year 2024 Earnings Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

### HEALTH SERVICES SEGMENT

<i>In millions</i>	Year Ending December 31,	
	2025E	2024
	At Least	Actual
Operating income (GAAP measure)	\$ 6,942	\$ 6,937
Amortization of intangible assets	598	595
Net realized capital gains	—	(289)
Adjusted operating income	\$ 7,540	\$ 7,243

### PHARMACY & CONSUMER WELLNESS SEGMENT

<i>In millions</i>	Year Ending December 31,	
	2025E	2024
	At Least	Actual
Operating income (GAAP measure)	\$ 5,232	\$ 4,770
Amortization of intangible assets	246	253
Restructuring charges <sup>(8)</sup>	—	747
Office real estate optimization charges <sup>(9)</sup>	2	4
Adjusted operating income	\$ 5,480	\$ 5,774

### ADJUSTED EFFECTIVE INCOME TAX RATE

The following are reconciliations of the projected effective income tax rate to the projected adjusted effective income tax rate:

#### CONSOLIDATED

	Year Ending December 31,	
	2025	2024
	Estimated	Actual
Effective income tax rate (GAAP measure)	23.8 %	25.4 %
Impact of non-GAAP adjustments <sup>(12)</sup>	1.7	(0.1)
Adjusted effective income tax rate	25.5 %	25.3 %

# Q4 and Full-Year 2024 Earnings

## Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

---

### Endnotes

- (1) Represents short-term debt and total long-term debt as of December 31, 2024 and December 31, 2023.
- (2) Represents a 50% equity credit related to the Company's issuance of \$3 billion of junior subordinated notes in December 2024.
- (3) Represents the current and long-term portion of operating lease liabilities reported on the Company's consolidated balance sheets as of December 31, 2024 and December 31, 2023.
- (4) Represents the net present value of payments related to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities as of December 31, 2024 and December 31, 2023.
- (5) In 2024, the gain on early extinguishment of debt relates to the Company's repayment of approximately \$2.6 billion of its outstanding senior notes in December 2024, pursuant to its tender offer for such senior notes.
- (6) Represents operating lease costs for the years ended December 31, 2024 and December 31, 2023, respectively.
- (7) The acquisition-related transaction and integration costs relate to the acquisitions of Signify Health, Inc. ("Signify Health") and Oak Street Health, Inc. ("Oak Street Health").
- (8) During 2024, the restructuring charges are primarily comprised of a store impairment charge, corporate workforce optimization costs, including severance and employee-related costs, a stock-based compensation charge and other asset impairment and related charges associated with the discontinuation of certain non-core assets. During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it plans to close additional retail stores in 2025, and, accordingly, it recorded a store impairment charge to write down the associated operating and financing lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company's best estimate of their fair value. During 2023, the restructuring charges are primarily comprised of severance and employee-related costs, asset impairment charges and a stock-based compensation charge.
- (9) The office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company's evaluation of corporate office real estate space in response to its ongoing flexible work arrangement.
- (10) The opioid litigation charge relates to a change in the Company's accrual related to ongoing opioid litigation matters.
- (11) The loss on assets held for sale relates to the long-term care ("LTC") business within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company's best estimate of the ultimate selling price which reflected its estimated fair value less costs to sell. As of the third quarter of 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values.
- (12) Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision. The 2025 projected adjusted effective income tax rate also excludes certain tax benefits related to anticipated IRS approval of a prior year matter.